We are live on
!
Find out more
Bellevue Group Portfolio holdings
AUM
$4.75B
Turnover
23.84%
1-Year Est. Return
68.58%
This Fund
S&P 500
This Quarter
Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
(-20%)
Cap. Flow
-$834M
Cap. Flow
% of AUM
-19.85%
Top 10 Holdings %
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40
Avg Time Held
3.8
years
Top 10 Avg Time Held
2.6
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$203M |
| 2 |
Gilead Sciences
GILD
|
+$156M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$146M |
| 4 |
Amgen
AMGN
|
+$98.7M |
| 5 |
Viridian Therapeutics
VRDN
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$350M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$235M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$225M |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$190M |
| 5 |
Amicus Therapeutics
FOLD
|
+$153M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| 2 | Energy | 0.07% |
| 3 | Technology | 0.06% |
| 4 | Miscellaneous | 0.05% |
| 5 | Financials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
Adobe
ADBE
$95.2B
| $292K | 0.01% |
1,200
| – | – |
2025 Q4
1 quarter
|
|
127
Amazon
AMZN
$2.69T
| $282K | 0.01% |
1,353
-2,188
| -62% | -$482K |
2025 Q1
4 quarters
|
|
128
Travere Therapeutics
TVTX
$4.68B
| $264K | 0.01% |
8,899
+5,072
| +133% | +$152K |
2025 Q4
1 quarter
|
|
129
Halozyme
HALO
$13.7B
| $249K | 0.01% |
+3,857
| New | +$272K |
2026 Q1
0 quarters
|
|
130
Olema Pharmaceuticals
OLMA
$577M
| $245K | 0.01% |
16,443
+12,541
| +321% | +$279K |
2025 Q4
1 quarter
|
|
131
CRISPR Therapeutics
CRSP
$4.75B
| $239K | 0.01% |
5,016
+3,136
| +167% | +$165K |
2025 Q4
1 quarter
|
|
132
Tempus AI
TEM
$11.7B
| $224K | 0.01% |
4,950
+174
| +4% | +$9.89K |
2024 Q2
7 quarters
|
|
133
Cardinal Health
CAH
$58.6B
| $182K | ﹤0.01% |
863
-6,806
| -89% | -$1.47M |
2023 Q4
9 quarters
|
|
134
PTC Therapeutics
PTCT
$4.95B
| $132K | ﹤0.01% |
1,935
-4,828
| -71% | -$342K |
2024 Q4
5 quarters
|
|
135
IQVIA
IQV
$43.8B
| $126K | ﹤0.01% |
740
-40,527
| -98% | -$7.91M |
2020 Q1
24 quarters
|
|
136
Ascendis Pharma A/S
ASND
$14.8B
| $123K | ﹤0.01% |
536
-23,794
| -98% | -$5.33M |
2024 Q4
5 quarters
|
|
137
Abivax
ABVX
$7.59B
| $117K | ﹤0.01% |
+1,048
| New | +$124K |
2026 Q1
0 quarters
|
|
138
Caris Life Sciences
CAI
$8.6B
| $115K | ﹤0.01% |
6,418
| – | – |
2025 Q2
3 quarters
|
|
139
Arrowhead Research
ARWR
$7.92B
| $96.9K | ﹤0.01% |
1,545
-10,005
| -87% | -$633K |
2025 Q4
1 quarter
|
|
140
Alphabet (Google) Class A
GOOGL
$4.16T
| $90.3K | ﹤0.01% |
314
-1,752
| -85% | -$550K |
2025 Q1
4 quarters
|
|
141
Rhythm Pharmaceuticals
RYTM
$5.92B
| $88.4K | ﹤0.01% |
1,016
-6,488
| -86% | -$631K |
2023 Q3
10 quarters
|
|
142
Agilent Technologies
A
$48.7B
| $75.7K | ﹤0.01% |
664
+314
| +90% | +$39.8K |
2023 Q4
9 quarters
|
|
143
Labcorp
LH
$25.7B
| $74.7K | ﹤0.01% |
280
-5,389
| -95% | -$1.46M |
2016 Q1
40 quarters
|
|
144
NVIDIA
NVDA
$5.18T
| $71.2K | ﹤0.01% |
408
-3,525
| -90% | -$647K |
2023 Q4
9 quarters
|
|
145
Microsoft
MSFT
$3.92T
| $63.7K | ﹤0.01% |
172
-1,110
| -87% | -$464K |
2023 Q4
9 quarters
|
|
146
Zoetis
ZTS
$32.6B
| $63K | ﹤0.01% |
533
-196
| -27% | -$24.2K |
2023 Q1
12 quarters
|
|
147
BridgeBio Oncology
BBOT
$227M
| $62.5K | ﹤0.01% |
+6,982
| New | +$75K |
2026 Q1
0 quarters
|
|
148
Incyte
INCY
$22.9B
| $45.7K | ﹤0.01% |
486
-4,287
| -90% | -$428K |
2016 Q1
40 quarters
|
|
149
Mettler-Toledo International
MTD
$32.4B
| $45.4K | ﹤0.01% |
36
-2
| -5% | -$2.7K |
2023 Q4
9 quarters
|
|
150
Wave Life Sciences
WVE
$611M
| $38.1K | ﹤0.01% |
5,261
-1,485,257
| -100% | -$19.3M |
2019 Q2
27 quarters
|
|
Similar funds
PTC
Bellevue Group's Q1 2026 Portfolio in Review
As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.
Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.
- Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
- Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
- Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
- Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
- Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
- Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
- Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.